Darbepoetin alfa protects the rat heart against infarction: Dose-response, phase of action, and mechanisms

Journal of Cardiovascular Pharmacology

Volumn 49, Issue 6, 2007, Pages 337-345

  Baker, John E ^a,b   Kozik, Deborah ^a   Hsu, Anna K ^a   Fu, Xiangping ^a   Tweddell, James S ^a,b   Gross, Garrett J ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b CHILDREN S HOSPITAL OF WISCONSIN   (United States)

Author keywords

Infarction; Ischemia; MAP kinases; Potassium channel; Receptors

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 MORPHOLINO 8 PHENYLCHROMONE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 5 HYDROXYDECANOIC ACID; ADENOSINE TRIPHOSPHATE; CLAMIKALANT; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; POTASSIUM CHANNEL; PROTEIN KINASE B; TROPONIN I; WORTMANNIN;

ACUTE HEART INFARCTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG MECHANISM; HEART INFARCTION SIZE; HEART MUSCLE ISCHEMIA; HEART MUSCLE NECROSIS; HEART MUSCLE REPERFUSION; HEART PROTECTION; HEART RATE; HEMATOCRIT; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; PRIORITY JOURNAL; RAT; SARCOLEMMA; THROMBOCYTE COUNT; TREATMENT RESPONSE;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; CARDIOTONIC AGENTS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME ACTIVATION; ENZYME INHIBITORS; ERYTHROPOIETIN; HEART; MALE; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY; MYOCARDIUM; POTASSIUM CHANNELS; RATS; RATS, SPRAGUE-DAWLEY;

EID: 34347212063     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/FJC.0b013e318040cf81     Document Type: Article

References (34)

1. Mancini DM, Katz SD, Lang CC, et al. Effect of erythropoietin on exercise capacity in patients with moderate to severe chronic heart failure. Circulation. 2003;107:294-299.
2. Silverberg DS, Wexler D, Blum M, et al. The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations. J Am Coll Cardiol. 2000;35:1737-1744.
3. Calvillo L, Latini R, Kajstura J, et al. Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling. Proc Natl Acad Sci U S A. 2003;100:4802-4806.
4. Eschbach JW, Egrie JC, Downing MR, et al. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. N Engl J Med. 1987;316:73-78.
5. Kilic E, Kilic U, Soliz J, et al. Brain-derived erythropoietin protects from focal cerebral ischemia by dual activation of ERK-1/-2 and Akt pathways. Faseb J. 2005;19:2026-2028.
6. Egrie JC, Dwyer E, Browne JK, et al. Darbepoetin alfa has a longer circulating half-life and greater in vivo potency than recombinant human erythropoietin. Exp Hematol. 2003;31:290-299.
7. Cleland JG, Sullivan JT, Ball S, et al. Once-monthly administration of darbepoetin alfa for the treatment of patients with chronic heart failure and anemia: a pharmacokinetic and pharmacodynamic investigation. J Cardiovasc Pharmacol. 2005;46:155-161.
8. Bahlmann FH, Song R, Boehm SM, et al. Low-dose therapy with the long-acting erythropoietin analogue darbepoetin alpha persistently activates endothelial Akt and attenuates progressive organ failure. Circulation. 2004;110:1006-1012.
9. Shi Y, Hutchins W, Su J, et al. Delayed cardioprotection with isoflurane: role of reactive oxygen and nitrogen. Am J Physiol. 2005;288:H175-H184.
10. Gross ER, Peart JN, Hsu AK, et al. K(ATP) opener-induced delayed cardioprotection: involvement of sarcolemmal and mitochondrial K(ATP) channels, free radicals and MEK1/2. J Mol Cell Cardiol. 2003;35:985-992.
11. Shi Y, Hutchins W, Ogawa H, et al. Increased Resistance to Myocardial Ischemia in the Brown Norway vs. Dahl S Rat: Role of Nitric Oxide Synthase and Hsp90. J Mol Cell Cardiol. 2005;38:625-635.
12. Cai Z, Manalo DJ, Wei G, et al. Hearts from rodents exposed to intermittent hypoxia or erythropoietin are protected against ischemia-reperfusion injury. Circulation. 2003;108:79-85.
13. Lipsic E, van der Meer P, Henning RH, et al. Timing of erythropoietin treatment for cardioprotection in ischemia/reperfusion. J Cardiovasc Pharmacol. 2004;44:473-479.
14. Parsa CJ, Matsumoto A, Kim J, et al. A novel protective effect of erythropoietin in the infarcted heart. J Clin Invest. 2003;112:999-1007.
15. Tramontano AF, Muniyappa R, Black AD, et al. Erythropoietin protects cardiac myocytes from hypoxia-induced apoptosis through an Akt-dependent pathway. Biochem Biophys Res Commun. 2003;308:990-994.
16. Aranesp. Aranesp (darbepoetin alfa) prescribing information. Thousand Oaks, CA, USA; 2003.
17. Allaf ME, Hoke A, Burnett AL. Erythropoietin promotes the recovery of erectile function following cavernous nerve injury. J Urol. 2005;174:2060-2064.
18. Bahlmann FH, De Groot K, Spandau JM, et al. Erythropoietin regulates endothelial progenitor cells. Blood. 2004;103:921-916.
19. Yazicioglu L, Eryilmaz S, Sirlak M, et al. Recombinant human erythropoietin administration in cardiac surgery. J Thorac Cardiovasc Surg. 2001;122:741-745.
20. Coyle D, Lee KM, Fergusson DA, et al. Cost effectiveness of epoetin-alpha to augment preoperative autologous blood donation in elective cardiac surgery. Pharmacoeconomics. 2000;18:161-171.
21. Kiyama H, Ohshima N, Imazeki T, et al. Autologous blood donation with recombinant human erythropoietin in anemic patients. Ann Thorac Surg. 1999;68:1652-1656.
22. Sowade O, Ziemer S, Sowade B, et al. The effect of preoperative recombinant human erythropoietin therapy on platelets and hemostasis in patients undergoing cardiac surgery. J Lab Clin Med. 1997;129:376-383.
23. Yellon DM, Opie LH. Postconditioning for protection of the infarcting heart. Lancet. 2006;367:456-458.
24. Lipsic E, van der Meer P, Voors AA, et al. A single bolus of a long-acting erythropoietin analogue darbepoetin alfa in patients with acute myocardial infarction: a randomized feasibility and safety study. Cardiovasc Drugs Ther. 2006;20:135-141.
25. Shi Y, Rafiee P, Su J, et al. Acute cardioprotective effects of erythropoietin in infant rabbits are mediated by activation of protein kinases and potassium channels. Basic Res Cardiol. 2004;99:173-182.
26. Wright GL, Hanlon P, Amin K, et al. Erythropoietin receptor expression in adult rat cardiomyocytes is associated with an acute cardioprotective effect for recombinant erythropoietin during ischemia-reperfusion injury. Faseb J. 2004;18:1031-1033.
27. Parsa CJ, Kim J, Riel RU, et al. Cardioprotective effects of erythropoietin in the reperfused ischemic heart: a potential role for cardiac fibroblasts. J Biol Chem. 2004;279:20655-20662.
28. Miki T, Miura T, Yano T, et al. Alteration in erythropoietin-induced cardioprotective signaling by postinfarct ventricular remodeling. J Pharmacol Exp Ther. 2006;317:68-75.
29. Hirata A, Minamino T, Asanuma H, et al. Erythropoietin enhances neovascularization of ischemic myocardium and improves left ventricular dysfunction after myocardial infarction in dogs. J Am Coll Cardiol. 2006;48:176-184.
30. Rafiee P, Shi Y, Su J, et al. Erythropoietin protects the infant heart against ischemia-reperfusion injury by triggering multiple signaling pathways. Basic Res Cardiol. 2005;100:187-197.
31. Cole WC, McPherson CD, Sontag D. ATP-regulated K+ channels protect the myocardium against ischemia/reperfusion damage. Circ Res. 1991;69:571-581.
32. Garlid KD, Paucek P, Yarov-Yarovoy V, et al. Cardioprotective effect of diazoxide and its interaction with mitochondrial ATP-sensitive K+ channels. Potential mechanism of cardioprotection. Circ Res. 1997;81:1072-1082.
33. Noma A. ATP-regulated K+ channels in cardiac muscle. Nature. 1983;305:147-148.
34. Gross GJ, Peart JN. KATP channels and myocardial preconditioning: an update. Am J Physiol Heart Circ Physiol. 2003;285:H921-H930.